Genmab/$GMAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Ticker

$GMAB
Sector
Primary listing

Employees

2,639

Headquarters

Copenhagen, Denmark

Genmab Metrics

BasicAdvanced
$20B
1.47
$21.62
0.80
-

What the Analysts think about Genmab

Analyst ratings (Buy, Hold, Sell) for Genmab stock.

Bulls say / Bears say

Genmab announced encouraging Phase II results for Arzerra in untreated CLL, with overall response rates of 77% and 73%, suggesting promise as a first-line treatment (Reuters)
Johnson & Johnson’s Q2 2025 earnings benefited from Darzalex, which delivered $3.54 billion in sales and led J&J to increase its full-year sales guidance to $93.2–$93.6 billion, supporting Genmab’s future royalty income (Reuters)
Genmab’s March deal allowed it to shift resources from HexaBody-CD38 to its late-stage proprietary pipeline, strengthening confidence in wholly owned assets like Rina-S and acasunlimab, both now in Phase 3 (Genmab)
J&J’s decision to discontinue HexaBody-CD38 forced Genmab to terminate development, highlighting pipeline risk and the loss of near-term revenue diversification opportunities (Genmab)
Morphosys AG has filed a patent infringement lawsuit against Genmab and Janssen over daratumumab, introducing legal uncertainties and possible royalty obligations for Genmab’s leading product (Reuters)
Genmab’s shares dropped to their lowest since mid-2003 despite increased retail interest, showing significant investor doubts about its valuation and growth outlook (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

Genmab Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Genmab Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GMAB

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs